CN1152874A - 共聚物组成改进的共聚物-1 - Google Patents

共聚物组成改进的共聚物-1 Download PDF

Info

Publication number
CN1152874A
CN1152874A CN95194101A CN95194101A CN1152874A CN 1152874 A CN1152874 A CN 1152874A CN 95194101 A CN95194101 A CN 95194101A CN 95194101 A CN95194101 A CN 95194101A CN 1152874 A CN1152874 A CN 1152874A
Authority
CN
China
Prior art keywords
copolymer
fraction
molecular weight
kilodaltons
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN95194101A
Other languages
English (en)
Other versions
CN1174753C (zh
Inventor
E·康菲诺
M·塞拉
D·泰特包姆
R·阿农
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1152874(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN1152874A publication Critical patent/CN1152874A/zh
Application granted granted Critical
Publication of CN1174753C publication Critical patent/CN1174753C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Abstract

本发明涉及一种改进组成的共聚物-1，其含有基本上不含分子量大于40千道尔顿的共聚物-1种类。

Description

共聚物组成改进的共聚物-1
本申请是1994年11月23日递交的U.S.S.N.08/344248的部分后续申请，该申请是1994年5月24日递交的U.S.S.N.08/248037的后续。
发明背景
共聚物-1是髓鞘碱性蛋白(MBP)的合成多肽类似物，髓鞘碱性蛋白是髓鞘的天然成分。已表明其是多发性硬化症的有效的治疗剂(欧洲免疫学杂志[1971]1：242；神经科学杂志[1977]31：433)。本文所引用的所有参考文献都引入本文以供参考。早在50年代，在多发性硬化症的免疫疗法中对共聚物-1的观察表明髓鞘碱性蛋白成分，如MBP可阻止或控制实验性自身免疫脑脊髓炎(EAE)。EAE是一种诱发于敏感动物的类似于多发性硬化症的疾病。
共聚物-1是由Drs.Sela、Arnon及其合作者在Weizmann研究所(Rehovot，以色列)研究的。据示它可抑制EAE(欧洲免疫学杂志[1971]1：242；美国专利3,849,550)。最近表明共聚物-1有利于缓解多发性硬化症的恶化(新英格兰医学杂志[1987]317：406)。采用每日注射共聚物-1治疗的患者与对照组患者相比几乎没有恶化并且他们的残疾加剧较轻微。
共聚物-1是多肽的混合物，由丙氨酸、谷氨酸、赖氨酸和酪氨酸组成，摩尔比约为6∶2∶5∶1。它是通过化学聚合四种氨基酸形成的产物(平均分子量为23000道尔顿)而合成的(美国专利3849550)。
本发明的目的是提供一种改进组成的共聚物-1。发明概述
本发明涉及一种共聚物-1组合物，该组合物基本上不含分子量大于40千道尔顿(KDa)的共聚物-1种类。
本发明另外涉及一种在分子量约为2KDa至20KDa范围内摩尔分级超过75％的共聚物-1。
另外，本发明涉及一种平均分子量约为4至8.6KDa的共聚物-1。
此外，本发明涉及一种药物组合物的以及用上述共聚物-1治疗多发性硬化症的方法。附图简述
图1表示三批共聚物-1的分子量分布，显示出分子量大于40KDa种类的比例。图2表示与摩尔分级有关的相似数据。发明详述
本发明涉及一种共聚物-1组合物，该组合物基本上不含分子量大于40千道尔顿(KDa)的共聚物-1种类。优选地，该组合物含有少于5％的分子量为40KDa或更高的共聚物-1种类。更优选该组合物含有少于2.5％的分子量为40KDa或更高的共聚物-1种类。
本发明另外涉及一种在分子量约为2KDa至20KDa范围内摩尔分级超过75％的共聚物-1。
此外，本发明涉及一种平均分子量约为4至8.6KDa的共聚物-1。更具体地说，本发明涉及一种平均分子量约为4至8KDa的共聚物-1以及平均分子量约为6.25至8.4Kda的共聚物-1。
本发明的共聚物-1可以通过本领域已知的方法制备，例如美国专利3849550中公开的方法，其中于环境温度将酪氨酸、丙氨酸、γ-谷氨酸苄酯以及E-N-三氟乙酰赖氨酸的N-羧酸酐在无水二噁烷中聚合，二乙胺作为引发剂。用溴化氢的冰醋酸溶液脱去谷氨酸的γ-羧基，然后用1M哌啶从赖氨酸残基上除去三氟乙酰基。对于本发明的目的而言，术语“环境温度”和“室温”应理解成从约20至约26℃的温度。
具有所需范围分子量的共聚物-1可以通过已知方法获得。该类方法包括将含有高分子量种类的共聚物-1进行色谱并收集不含非所需种类的部分，或者通过部分酸或酶水解除去高分子量的种类，其后通过透析或超滤进行纯化。另外获得所需分子量范围的共聚物-1的方法是通过制备氨基酸是被保护的所需种类，然后直接除去保护即得所需种类。本发明的组合物可以通过本领域常规的已知方法配制。优选地，将组合物冻干并制成适于皮下注射用的水溶液。可任选地，也可将共聚物-1配制成本领域已知的用于制备肽类药物的口服、鼻用、口腔用或直肠用制剂的各种形式。
典型地，每日以20mg的剂量将共聚物-1给予多发性硬化症患者。
本发明通过下述实施例说明，但并非限定本发明。实施例1制备低毒性共聚物-1的色谱法
按照本领域已知的方法如美国专利3849550的方法制备两组共聚物-1。
如下文所述将一组用色谱分离。
在Superformance 26 Merck药筒中按照生产商的说明制备凝胶过滤用柱-FRACTOGEL TSK HW55(600×26mm)。将此柱用水平衡，注射丙酮溶液用于总体积测定。用0.2M的乙酸铵缓冲液(pH 5.0)平衡该柱。将30ml共聚物-1样品(20mg/ml，在0.2M pH值为5.0的乙酸铵中)装上柱，每10分钟收集一次级分。在120-130分钟之间分离含有平均分子量为7-8KDa的级分(A批)。分子量分析
在UVIKON 810分光光度计上测定275nm的紫外吸收。将样品稀释以获得低于1个吸收单位的紫外吸收。在校准后的凝胶过滤柱(Superose12)上测定两批产品的分子分布。
发现共聚物-1的A批平均分子量为7-8Kda.该批产品的2.5％具有高于32KDa的分子量，但是在该批产品中不存在分子量高于40KDa的共聚物-1种类。
共聚物-1的另一批(不进行色谱法)平均分子量为12KDa.该批产品的2.5％具有高于42KDa的分子量，该批产品中总共聚物-1种类的5％具有高于40KDa的分子量。实施例2毒性分析
A：体内
将平均分子量为7.3和8.4KDa(低于2.5％的共聚物-1种类超过40KDa)和22KDa(多于5％的共聚物-1种类超过40KDa)的三批共聚物-1进行如下毒性试验。在每种情况下每个实验组使用5只小鼠。方法
将共聚物-1溶于蒸馏水中得到含2mg/ml的活性成分的溶液。将0.5ml测试溶液注射到每只小鼠的外侧尾静脉。观察48小时期间中小鼠的死亡率和相关临床症状。注射后10分钟、24小时和48小时记录观察结果。如果在48小时后，全部动物仍存活并且没有观察到不良症状，则指明该组为“无毒”。但是，如果有一只或多只的小鼠死亡或者表现出不良症状，则指明该组为“毒性”。
平均分子量为7.3和8.4KDa批的产品都被指明是“无毒”，而平均分子量为22KDa的组在48小时后，5只小鼠中有3只死亡，因此指明其为“毒性”。B：体外RBL-脱颗粒试验I.引言
噬碱细胞释放的组胺(或者5-羟色胺)是一种直接过敏性的体外模型。将大鼠噬碱白细胞系(RBL-2H3)培养成特征为高敏、均一、易于在培养物及再生体系中维持的细胞系(E.L.Basumian，C.Isersky，M.G.petrino和R.P.Siraganian.欧洲免疫学杂志11，317(1981))。组胺释放的生理刺激包括抗原结合到膜结合IgE分子上，导致后者交联，然后引发复杂的生化级联。除了这些生理性免疫球蛋白介导的引发剂以外，也可通过不同的非IgE介导剌激诱导脱粒。其中有各种肽类和合成聚合物，例如聚赖氨酸(R.P.Siraganian.药理学动向，10月，432(1983))。因此，用RBL脱粒试验筛选出可引起脱粒从而导致有害的局部和/或全身副作用的共聚物-1。II.试验方法原理
将大鼠噬碱白细胞(RBL-2H3)用[3H]-5-羟色胺加载，然后与100μg待测共聚物-1一起培养。可诱导非特异性脱粒的共聚物-1组可将[3H]-5-羟色胺释放到培养基中。通过液闪计数仪计数培养基中的放射性，在沉淀细胞中测定结合到细胞中的总放射标记的5-羟色胺。脱粒百分数是以从总结合中的释放出的5-羟色胺百分比计算的。III.结果
分析平均分子量在6,250-14,500之间的四批共聚物-1的分子量大于40KDa种类的和RBL脱粒的百分数％。结果汇总于下表。
平均分子量(道尔顿) 分子量大于40KDa种类的百分数(％) 5-羟色胺释放百分数(％)
    6,250     ＜2.5     12.4
    7,300     ＜2.5     21.0
    13,000     ＞5     66.9
    14,500     ＞5     67.8
从中可看出，当高分子量种类的百分数低时(＜2.5)，5-羟色胺的释放百分数(表示毒性)则低，反之亦然。实施例3三氟乙酰基-共聚物-1的制备
按照Teitelbaum等在《欧洲免疫学杂志》第1卷第242页(1971)中描述的方法由溶于3.5升二噁烷中的酪氨酸的N-羧酸酐(18g)、丙氨酸(50g)、γ-谷氨酸苄酯(35g)的N-羧酸酐和三氟乙酰赖氨酸制备保护起来的共聚物-1。
通过加入0.01-0.02％二乙胺引发聚合过程。将反应混合物于室温搅拌24小时，然后倒入10升水中。过滤产物(被保护的共聚物-1)，用水洗涤并干燥。室温下用33％氢溴酸的冰醋酸溶液搅拌处理被保护的共聚物-16至12小时以除去谷氨酸盐中γ苄基保护基。将产物倒入过量水中，过滤，洗涤并干燥，得到三氟乙酰基-共聚物-1。实施例4三氟乙酰基-共聚物-1的制备
按照Teitelbaum等在《欧洲免疫学杂志》第1卷第242页(1971)中描述的方法由溶于3.5升二恶烷中的酪氨酸的N-羧酸酐(18g)、丙氨酸(50g)、γ-谷氨酸苄酯(35g)和三氟乙酰赖氨酸制备保护起来的共聚物-1。
通过进入0.01-0.02％二乙胺引发聚合过程。将反应混合物于室温搅拌24小时，然后倒入10升水中。过滤产物(被保扩的共聚物-1)，用水洗涤并干燥。
用33％HBr的冰醋酸溶液处理被保护的共聚物-1以从谷氨酸残基的5-甲酸酯中除去Ω苄基保护基并且将聚合物分裂成较小的多肽。获得分子量为7,000±2,000道尔顿的共聚物-1所需时间取决于反应温度和被保护的共聚物-1的大小。在20-28℃之间的温度于不同时间段如10-50小时对每批产品进行测试反应。计算有关这些小规模反应的分子量结果，描绘分子量对时间的曲线。由该曲线计算获得平均分子量为7000±2,000道尔顿的共聚物-1所需时间并将其应用于较大规模的反应中。平均而言，在26℃操作的时间为17小时。将产物倒入过量水中，过滤，洗涤并干燥，得到三氟乙酰基-共聚物-1。低毒性共聚物-1的制备
将20g三氟乙酰基-共聚物-1分散在1升水中，加入100g哌啶。室温搅拌混合物24小时，过滤。将粗共聚物-1溶液分配到透析袋中，于10-20℃水中透析，直至达到pH＝8。然后将其在约0.3％乙酸中透析，再用水透析直至达到pH＝5.5-6.0。然后将溶液浓缩并冻干。

Claims (11)

1.一种共聚物-1级分，基本上不含分子量大于40千道尔顿的共聚物-1种类。
2.一种共聚物-1级分，其中所述级分含有少于5％的分子量大于40千道尔顿的共聚物-1种类。
3.权利要求2的共聚物-1级分，其中的级分含有少于2.5％的分子量大于40千道尔顿的共聚物-1种类。
4.权利要求2的共聚物-1级分，其中超过75％的所述级分的分子量在约2千道尔顿至约20千道尔顿范围内。
5.一种共聚物-1级分，其中所述共聚物-1的平均分子量为约4至约8千道尔顿。
6.一种共聚物-1级分，其中所述共聚物-1的平均分子量为约6.25至约8.4千道尔顿。
7.一种治疗多发性硬化症的组合物，含有一种药学有效量的共聚物-1级分以及可药用载体，其中所述级分含有少于5％的分子量大于40千道尔顿的共聚物-1种类。
8.权利要求7的组合物，其中的共聚物-1级分含有少于2.5％的分子量大于40千道尔顿的共聚物-1种类。
9.权利要求7的组合物，其中所述级分中超过75％的所述共聚物-1的分子量在约2千道尔顿至约20千道尔顿范围内。
10.一种治疗多发性硬化症的组合物，含有一种药学有效量的共聚物-1级分以及可药用载体，其中所述级分中的所述共聚物-1的平均分子量为约4至8千道尔顿。
11.一种治疗多发性硬化症的组合物，含有一种药学有效量的共聚物-1级分以及可药用载体，其中所述级分中的所述共聚物-1的平均分子量为约6.25至8.4千道尔顿。
CNB951941011A 1994-05-24 1995-05-23 共聚物组成改进的共聚物-1 Expired - Lifetime CN1174753C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US08/248,037 1994-05-24
US34424894A 1994-11-23 1994-11-23
US08/344,248 1994-11-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB200410064296XA Division CN1310673C (zh) 1994-05-24 1995-05-23 含多肽的多分散混合物的组合物及其药物组合物

Publications (2)

Publication Number Publication Date
CN1152874A true CN1152874A (zh) 1997-06-25
CN1174753C CN1174753C (zh) 2004-11-10

Family

ID=26939072

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB951941011A Expired - Lifetime CN1174753C (zh) 1994-05-24 1995-05-23 共聚物组成改进的共聚物-1
CNB200410064296XA Expired - Lifetime CN1310673C (zh) 1994-05-24 1995-05-23 含多肽的多分散混合物的组合物及其药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB200410064296XA Expired - Lifetime CN1310673C (zh) 1994-05-24 1995-05-23 含多肽的多分散混合物的组合物及其药物组合物

Country Status (31)

Country Link
US (11) US5800808A (zh)
EP (1) EP0762888B1 (zh)
JP (2) JPH10500955A (zh)
KR (1) KR100403750B1 (zh)
CN (2) CN1174753C (zh)
AT (1) ATE212857T1 (zh)
AU (1) AU2602195A (zh)
BR (2) BRPI9507758B1 (zh)
CA (1) CA2191088C (zh)
CZ (1) CZ292247B6 (zh)
DE (2) DE69525340T2 (zh)
DK (1) DK0762888T3 (zh)
EE (1) EE03423B1 (zh)
ES (1) ES2172586T3 (zh)
FI (1) FI120236B (zh)
GE (1) GEP20002205B (zh)
HK (1) HK1008657A1 (zh)
HU (1) HU223473B1 (zh)
IL (2) IL113812A (zh)
LU (1) LU90987I2 (zh)
MD (1) MD1443G2 (zh)
NL (1) NL300096I2 (zh)
NO (1) NO324528B1 (zh)
NZ (1) NZ287335A (zh)
PL (1) PL181026B1 (zh)
PT (1) PT762888E (zh)
SI (1) SI0762888T1 (zh)
SK (1) SK283699B6 (zh)
TJ (1) TJ392B (zh)
UA (1) UA62908C2 (zh)
WO (1) WO1995031990A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166754B (zh) * 2004-09-09 2014-04-23 特瓦制药工业有限公司 使用纯化的氢溴酸制备多肽混合物的方法

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
AU2868699A (en) * 1998-02-13 1999-08-30 Autoimmune, Inc. Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000018794A1 (en) 1998-09-25 2000-04-06 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
JP2003522799A (ja) * 2000-02-18 2003-07-29 イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス コポリマー１の経口、経鼻および経肺投与製剤
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020037848A1 (en) * 2000-06-07 2002-03-28 Michal Eisenbach-Schwartz Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
WO2001097785A2 (en) * 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
IL137460A0 (en) 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
GB2369896A (en) 2000-12-06 2002-06-12 Marconi Comm Ltd Tunable optical filter actuator
KR100442122B1 (ko) * 2001-07-31 2004-07-30 한국전기연구원 영구 자석을 이용한 브러시리스 발전기
ATE475883T1 (de) * 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
CA2469092C (en) * 2001-12-06 2013-02-19 Yeda Research And Development Co. Ltd Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als)
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
JP5291878B2 (ja) 2003-01-07 2013-09-18 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 治療的免疫のためのコポリマー１を含む点眼ワクチン
PT1592384E (pt) * 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
CA2518079A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
EP1638581A2 (en) 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2005041933A1 (en) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries, Ltd. Nanoparticles for drug delivery
EP2301569B1 (en) 2003-11-12 2018-05-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
AU2004297044B2 (en) 2003-12-09 2010-12-09 Yeda Research And Development Co. Ltd. Method and vaccine comprising Copolymer 1 for treatment of psychiatric disorders
CA2556152A1 (en) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Peptide mixtures with immunomodulatory activity
MXPA06010043A (es) * 2004-03-01 2007-03-07 Peptimmune Inc Metodos y composiciones para el tratamiento de enfermedades autoinmunologicas.
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
EP1750741B1 (en) 2004-05-07 2015-12-02 Ares Trading S.A. Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
JP5274011B2 (ja) 2004-06-25 2013-08-28 アイディー バイオメディカル コーポレイション オブ ケベック 神経障害を治療するための組成物および方法
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
ES2331015T3 (es) * 2004-10-29 2009-12-18 Sandoz Ag Proceso para la preparacion de un glatiramero.
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
US20090191173A1 (en) * 2004-11-29 2009-07-30 Michal Eisenbach-Schwartz Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
SI1848415T1 (sl) * 2005-02-17 2013-08-30 Teva Pharmaceutical Industries Ltd. Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
CA2649296A1 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
AU2007244643B2 (en) 2006-04-28 2013-05-02 Momenta Pharmaceuticals, Inc. Methods of evaluating peptide mixtures
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
ES2605154T3 (es) 2006-06-28 2017-03-13 Yeda Research And Development Company Limited Copolímero 1 para el tratamiento de la degeneración macular relacionada con la edad
EP2046817B1 (en) * 2006-07-05 2009-12-16 Momenta Pharmaceuticals, Inc. Improved process for the preparation of copolymer-1
US8753833B2 (en) 2007-06-21 2014-06-17 Momenta Pharmaceuticals, Inc. Copolymer assay
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
EP2173766A1 (en) * 2007-07-31 2010-04-14 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
US9533037B2 (en) 2007-10-16 2017-01-03 Declion Holdings Llc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
JP2011504925A (ja) * 2007-11-28 2011-02-17 テバ ファーマシューティカル インダストリーズ リミティド 臨床的に確実な多発性硬化症の発症を遅延させる方法
EP2277050B2 (en) † 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
BRPI0918718A2 (pt) * 2008-08-07 2015-12-01 Scinopharm Taiwan Ltd síntese de acetato de glatirâmero
ES2537022T3 (es) * 2008-08-07 2015-06-01 Sigma-Aldrich Co. Llc Preparación de polilisina y poliornitina de bajo peso molecular con alto rendimiento
US9617313B2 (en) * 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
EP2414384B2 (en) * 2009-04-03 2023-05-03 Momenta Pharmaceuticals, Inc. Control of copolymer compositions
AU2009347384B2 (en) * 2009-06-04 2014-10-23 Council Of Scientific & Industrial Research A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
ATE549013T1 (de) * 2009-07-15 2012-03-15 Teva Pharma Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
EP3199172B1 (en) 2009-08-20 2018-07-11 Yeda Research and Development Co., Ltd. Dosing regimen for multiple sclerosis
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2699692T3 (es) 2010-01-04 2019-02-12 Mapi Pharma Ltd Sistema de depósito que comprende acetato de glatiramer
WO2011086470A1 (en) 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
NZ603012A (en) * 2010-04-27 2015-01-30 Reddy’S Lab Ltd Dr Preparation of polypeptides and salts thereof
US20110287048A1 (en) 2010-05-20 2011-11-24 Round June L Antigen Specific Tregs and related compositions, methods and systems
WO2012016042A2 (en) 2010-07-29 2012-02-02 Dr. Reddy's Laboratories Ltd. Glatiramer acetate molecular weight markers
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
EP2675824B1 (en) 2011-02-14 2017-09-27 USV Private Limited Copolymer-1, process for preparation and analytical methods thereof
WO2012143924A1 (en) * 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
JP6273200B2 (ja) 2011-07-12 2018-01-31 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 脂質含有ｐｓａ組成物、その単離の方法および使用の方法
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
EP2642290A1 (en) 2012-03-19 2013-09-25 Synthon BV Glatiramer acetate human monocytic cell line-based potency assay
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
CA2884267A1 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
WO2014060942A2 (en) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2014128079A1 (en) 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
PT2774640E (pt) 2013-03-08 2015-02-09 Teva Pharma Dispositivo injector reutilizável para seringa
EP2774639B1 (en) 2013-03-08 2014-12-10 Teva Pharmaceutical Industries, Ltd. Re-useable injector device for syringe
JP6553018B2 (ja) 2013-03-14 2019-07-31 マイラン・インコーポレイテッドＭｙｌａｎ Ｉｎｃ． 酢酸グラチラマー応答バイオマーカーｍＲＮＡ効力アッセイ
WO2014173463A1 (en) 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
CA2911826C (en) 2013-05-10 2022-08-23 California Institute Of Technology Probiotic prevention and treatment of colon cancer
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
CN104371012A (zh) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015061610A2 (en) * 2013-10-24 2015-04-30 Mylan Inc. Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
JP2017503169A (ja) 2013-12-31 2017-01-26 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
KR20230097209A (ko) 2014-03-12 2023-06-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107533058A (zh) 2015-03-01 2018-01-02 免疫阵列有限公司 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
EP3147667B1 (en) 2015-09-24 2019-06-12 CHEMI S.p.A. Analysis of the molecular weight distribution of complex polypeptide mixtures
EP3170836B1 (en) 2015-11-23 2018-10-24 Chemi SPA Rp-hplc analysis of complex polypeptide mixtures
CN107522774B (zh) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
BR112019003131A2 (pt) 2016-08-28 2019-05-21 Mapi Pharma Ltd. processo para preparar micropartículas contendo acetato de glatirâmero
BR112019003594A2 (pt) 2016-08-31 2019-05-21 Mapi Pharma Ltd sistemas depot que compreendem acetato de glatirâmero
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
AU2018270396A1 (en) 2017-05-15 2020-01-02 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
US11413311B2 (en) 2017-05-15 2022-08-16 Mapi Pharma Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
EP3765034A1 (en) 2018-03-12 2021-01-20 Yeda Research and Development Co. Ltd Treatment of a heart disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4444760A (en) 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
CA1279822C (en) 1985-06-18 1991-02-05 Robert L. Hunter Biologically-active copolymers
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US4828706A (en) 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (zh) * 1989-01-13 1989-08-03 Indag Gesellschaft Fuer Industriebedarf Mbh, 6904 Eppelheim, De
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
EP0613496B1 (en) * 1991-11-12 1999-01-20 E.I. Du Pont De Nemours And Company Collagen-like polypeptides
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1998049939A1 (en) 1997-05-06 1998-11-12 Quanta Vision Tissue analysis apparatus
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166754B (zh) * 2004-09-09 2014-04-23 特瓦制药工业有限公司 使用纯化的氢溴酸制备多肽混合物的方法

Also Published As

Publication number Publication date
EP0762888A1 (en) 1997-03-19
CA2191088C (en) 2004-09-28
ES2172586T3 (es) 2002-10-01
GEP20002205B (en) 2000-08-25
DK0762888T3 (da) 2002-05-27
EE9600170A (et) 1997-06-16
US6362161B1 (en) 2002-03-26
BRPI9507758B1 (pt) 2021-03-16
SK149396A3 (en) 1997-08-06
ATE212857T1 (de) 2002-02-15
CZ341096A3 (en) 1997-06-11
US20040106554A1 (en) 2004-06-03
IL113812A (en) 2000-06-29
JP2003105000A (ja) 2003-04-09
MD1443F1 (en) 2000-04-30
EP0762888B1 (en) 2002-02-06
CN1626238A (zh) 2005-06-15
CN1310673C (zh) 2007-04-18
SK283699B6 (sk) 2003-12-02
US6342476B1 (en) 2002-01-29
KR970703154A (ko) 1997-07-03
PL181026B1 (pl) 2001-05-31
CZ292247B6 (cs) 2003-08-13
AU2602195A (en) 1995-12-18
JP3715600B2 (ja) 2005-11-09
HU223473B1 (hu) 2004-07-28
FI120236B (fi) 2009-08-14
US6048898A (en) 2000-04-11
MD1443G2 (ro) 2000-11-30
US5981589A (en) 1999-11-09
PL317331A1 (en) 1997-04-01
EE03423B1 (et) 2001-06-15
UA62908C2 (uk) 2004-01-15
CN1174753C (zh) 2004-11-10
US7199098B2 (en) 2007-04-03
DE69525340T2 (de) 2002-09-19
HK1008657A1 (en) 1999-05-14
TJ392B (en) 2004-10-13
LU90987I2 (fr) 2003-02-25
NL300096I1 (nl) 2002-10-01
SI0762888T1 (en) 2002-08-31
NO964976D0 (no) 1996-11-22
NO324528B1 (no) 2007-11-12
DE69525340D1 (de) 2002-03-21
BR9507758A (pt) 1997-09-23
HU9603243D0 (en) 1997-01-28
US6620847B2 (en) 2003-09-16
FI964600A0 (fi) 1996-11-15
WO1995031990A1 (en) 1995-11-30
HUT75672A (en) 1997-05-28
PT762888E (pt) 2002-07-31
DE10299030I1 (de) 2003-01-23
US5800808A (en) 1998-09-01
US20050171286A1 (en) 2005-08-04
KR100403750B1 (ko) 2006-02-13
IL133890A0 (en) 2001-04-30
US7625861B2 (en) 2009-12-01
US8367605B2 (en) 2013-02-05
CA2191088A1 (en) 1995-11-30
FI964600A (fi) 1996-12-05
NZ287335A (en) 1999-02-25
US20120077754A1 (en) 2012-03-29
US20030064914A1 (en) 2003-04-03
IL113812A0 (en) 1995-08-31
EP0762888A4 (zh) 1997-04-16
US20070117757A1 (en) 2007-05-24
JPH10500955A (ja) 1998-01-27
US6054430A (en) 2000-04-25
NO964976L (no) 1997-01-23
US6939539B2 (en) 2005-09-06
NL300096I2 (nl) 2003-02-03

Similar Documents

Publication Publication Date Title
CN1174753C (zh) 共聚物组成改进的共聚物-1
CN103533951B (zh) 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
RU2161489C2 (ru) Усовершенствованный сополимер-1 в сополимерных композициях
AU2004202245B2 (en) Copolymer-1 Improvements in Compositions of Copolymers
AU741590B2 (en) Copolymer-1 improvements in compositions of copolymers
AU775214B2 (en) Copolymer-1 improvements in compositions of copolymers
JP3002213B2 (ja) ペプチドおよびこのペプチドを含有する薬剤
CN117510592A (zh) 一种生物活性肽及其在制备皮肤创伤修复化妆品的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20150523

Granted publication date: 20041110